State pharmaceutical firm Indofarma (INAF) suffered net loss of Rp721 billion in 2023, widened from Rp457.6 billion loss in 2022, as net sales fell 46.6% year on year (y/y) to Rp523.6 billion. Combined various issues at sister company Kimia Farma (KAEF), the Prabowo-Gibran administration should make a decision on the future of state companies in the pharmaceutical sector.To subscribe please click here
